ICER Affirms Sickle Cell Disease Gene Therapies Cost-Effective at $2 Million

A revised report from the Institute for Clinical Evaluation and Research (ICER) has reiterated that two experimental gene therapies for sickle cell disease (SCD) would likely be cost-effective if priced at $2 million.
Source: Drug Industry Daily